Clinical Trial: Open-label, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.

U.S., May 30 -- ClinicalTrials.gov registry received information related to the study (NCT07615101) titled 'Open-label, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.' on May 22.

Brief Summary: The investigators are imaging patients with newly diagnosed prostate cancer using a new Positron Emission Tomography (PET) imaging agent (68Ga-NYM032) in order to evaluate the safety and diagnostic performance.

Study Start Date: June 01

Study Type: INTERVENTIONAL

Condition: Prostate Cancer (Diagnosis)

Intervention: DRUG: 68-Ga-NYM032

IV injection

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Norroy Bioscience ...